To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: June 1, 2007
Last updated: March 19, 2014
Last verified: March 2014

To study different doses of MK0493 for safety, efficacy and tolerability in obese patients.

Condition Intervention Phase
Drug: MK0493
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Enrollment: 173
Study Start Date: July 2005
Study Completion Date: March 2006
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   21 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is between 21 and 65 years of age

Exclusion Criteria:

  • HIV positive as determined by medical history
  • Patient is pregnant, lactating or plans to become pregnant
  • Patient has undergone surgical treatment for obesity
  • Patient has undergone a surgical procedure within 4 weeks prior to Visit 1 or plans to undergo a surgical procedure during the study
  • Patient plans to consume more than 2 glasses of grapefruit juice per day during the study
  • Patient has participated in another clinical study (involving an investigational drug) within 3 months prior to restudy screening
  Contacts and Locations
Please refer to this study by its identifier: NCT00482196

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00482196     History of Changes
Other Study ID Numbers: 0493-017, 2007_577
Study First Received: June 1, 2007
Last Updated: March 19, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Nutrition Disorders
Body Weight
Signs and Symptoms processed this record on April 23, 2014